DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Preclinical evaluation of potential nilotinib cardiotoxicity.

Author(s): Wolf A, Couttet P, Dong M, Grenet O, Heron M, Junker U, Ledieu D, Mahl A, Marrer E, Persohn E, Pognan F, Zhou W, Tsao J, Roman D

Affiliation(s): Preclinical Safety, Novartis Institutes for Biomedical Research, CH-4009 Basel, Switzerland.

Publication date & source: 2011-05, Leuk Res., 35(5):631-7. Epub 2010 Dec 3.

Publication type: Research Support, Non-U.S. Gov't

In vitro, concentrations >/= 10 muM of nilotinib were needed to induce markers of cytotoxicity, apoptosis, and endoplasmic reticulum stress in both neonatal rat ventricular myocytes, a putative target tissue, and non-target heart fibroblasts, indicating a lack of cardiomyocyte-specific nilotinib toxicity in vitro. In rats, oral nilotinib treatment at 80 mg/kg for 4 weeks induced increased heart weight; however, this was not associated with relevant histopathological changes or effects on heart function. Thus, nilotinib at and above clinically relevant concentrations (4.27 muM) did not induce overt cardiovascular pathologies or heart failure in vitro or in vivo under study conditions. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017